



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date 22nd November, 2024

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code:532815

Symbol: SMSPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR"), we would like to inform you that BSE Limited (BSE) and National Stock Exchange of India Ltd (NSE), have imposed fines on the Company via their emails dated 21st November, 2024 for Non-Compliance of Regulation 19(1)(c) of SEBI (LODR) Regulations, 2015 pertaining to composition of Nomination and Remuneration Committee of the Company which stipulates that '*at least two-thirds of the Directors shall be Independent Directors.*'

Whereas the Company while re-constituting the Nomination and Remuneration Committee it was initially proposed comprise of three members, including two Independent Directors and one Non-Executive Director. However, during the Meeting finally, another Non-Executive Director was inadvertently inducted resulting in the Committee being constituted with four members w.e.f 12th August, 2024. It is pertinent to note that no Nomination and Remuneration Committee meetings were held, and no decisions were taken during this period. Hence, there was no material impact on the Company.

Upon subsequent review, the oversight was identified, and the Committee was reconstituted to align with the requirements of Regulation 19(1)(c) by removing one Non-Executive Director from the Committee with effect from 8th November 2024. Consequently, the Company complied with Regulation 19(1)(c) of SEBI (LODR) Regulations, 2015.

The details as required under SEBI Listing Regulations read with Circular no. SEBI/HO/CFD/CFD-PoD-1/P-CIR//2023/123 dated July 13, 2023 are provided below:

Name of the authority;	BSE Limited & National Stock Exchange of India Ltd.
-------------------------------	---



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Nature and details of the action(s) taken, initiated or order(s) passed	Fine of Rs. 2,000/- per day from 12th August, 2024 to 30th September, 2024 imposed by BSE Limited & National Stock Exchange of India Ltd, for non-compliance.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	21 st November, 2024
Details of the violation(s)/contravention(s) committed or alleged to be committed	Non-compliance of Regulation 19(1)(c) of SEBI LODR, with the requirements ' <i>at least two-thirds of the Directors shall be Independent Directors</i> ' pertaining to the composition of Nomination and Remuneration Committee of the Board for the period from 12 th August, 2024 to 08 th November, 2024.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact of such fines on the financial, operation or other activities of the Company.

It is respectfully submitted that the non-compliance with SEBI (LODR) Regulations was unintentional, and the Company did not deliberately or wilfully avoid fulfilling any obligations under the said regulations. The Company remains committed to ensuring full compliance with all applicable laws.

The Company is considering a proposal to file an application for the waiver of the fine imposed by the Stock Exchanges.

We request you to kindly take the above on record.

Thanking you

For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary & Compliance Officer